Yoshiyuki Kakehi

Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 174 publications

Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 27, 2025

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.

Journal: European urology

Published: August 04, 2025

Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis-final analysis of 3-year extended follow-up focusing on bone fractures.

Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis-final analysis of 3-year extended follow-up focusing on bone fractures.

Journal: International journal of clinical oncology

Published: November 14, 2024

Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).

Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).

Journal: BJU international

Published: June 18, 2024

Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan.

Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan.

Journal: International journal of clinical oncology

Published: March 25, 2024

Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner.

Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner.

Journal: Oncology reports

Published: August 17, 2023

Development and internal validation of a screening tool for chronic prostatitis (S-CP).

Development and internal validation of a screening tool for chronic prostatitis (S-CP).

Journal: World journal of urology

Published: July 04, 2023

Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.

Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.

Journal: International journal of clinical oncology

Published: August 17, 2022

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study.

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study.

Journal: BMC urology

Published: July 13, 2022

Antitumor Effects of Orally Administered Rare Sugar D-Allose in Bladder Cancer.

Antitumor Effects of Orally Administered Rare Sugar D-Allose in Bladder Cancer.

Journal: International journal of molecular sciences

Published: May 28, 2022

Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.

Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.

Journal: International journal of clinical oncology

Published: April 19, 2022

Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study.

Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study.

Journal: Japanese journal of clinical oncology

Published: March 17, 2022

Showing 1-12 of 174

Last Updated: 09/26/2026